Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.
Moreira
José M A
JM
Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen Ø, Denmark. jom@cancer.dk
Ohlsson
Gita
G
Gromov
Pavel
P
Simon
Ronald
R
Sauter
Guido
G
Celis
Julio E
JE
Gromova
Irina
I
D000818:Animals; D001665:Binding Sites; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D015153:Blotting, Western; D019556:COS Cells; D002522:Chlorocebus aethiops; D015180:Electrophoresis, Gel, Two-Dimensional; D020022:Genetic Predisposition to Disease; D006801:Humans; D007150:Immunohistochemistry; D008565:Membrane Proteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation; D011379:Prognosis; D040901:Proteomics / Q000379:methods*; D046888:Tissue Array Analysis; D001749:Urinary Bladder Neoplasms / Q000145:classification / Q000378:metabolism* / Q000473:pathology
C453739:BLCAP protein, human; D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D009363:Neoplasm Proteins